United States Patent 7,540,282: Inhaler Claim Scope, Patent Landscape, Exclusivity and Generic Entry Risk

U.S. Patent No. 7,540,282 protects a mechanically sequenced dry-powder inhaler built around a sealed medicament reservoir, a translating metering cup, pressure-relief control, bellows-assisted dosing, a ratcheting actuator, a mouthpiece cover, and a mechanical dose counter. The independent claim is directed to the reservoir-channel-cup interface. Claims 2 through 17 add progressively narrower mechanical, actuation, packaging, and dose-counting limitations.

The patent is a device patent rather than an active-ingredient patent. Its claims do not cover a chemical compound, a pharmaceutical composition, or a therapeutic method. They are directed to inhaler architecture and dose-metering operation. Patent expiration cannot be calculated from the issue date alone because U.S. patent term generally runs from the effective nonprovisional filing date, subject to patent-term adjustment, terminal disclaimers, and applicable continuation practice.[1]

What does U.S. Patent 7,540,282 protect?

The patent protects an inhaler that meters dry powder from a sealed reservoir through a movable cup assembly. Claim 1 requires all of the following elements:

Claim 1 element	Technical function
Sealed reservoir	Stores medicament in an enclosed interior
Dispensing port	Provides the reservoir outlet
Linear channel	Receives and guides the metering assembly
Pressure-relief port	Controls pressure communication with the reservoir
Conduit	Connects the reservoir interior to the pressure-relief port
Movable cup assembly	Translates within the channel
Recess in the cup	Receives a dose from the reservoir
First sealing surface	Seals the dispensing port when the recess is displaced
Second sealing surface	Seals or unseals the pressure-relief port depending on cup position

The claim is operationally sequenced. When the recess aligns with the dispensing port, the recess receives medicament and the second sealing surface seals the pressure-relief port. When the cup moves away from the dispensing port, the first sealing surface closes the dispensing port and the second sealing surface unseals the pressure-relief port.

That sequencing is central to claim scope. A competing inhaler that uses a metering recess but lacks the claimed pressure-relief port, conduit, or dual sealing relationship would not literally satisfy claim 1.

How broad is independent claim 1?

Claim 1 has moderate breadth at the system level but substantial structural specificity. It does not require:

A particular active ingredient;
A specific dose strength;
A particular inhalation airflow;
A particular reservoir material;
A particular shape for the cup;
A specific mouthpiece;
A bellows;
A dose counter;
A particular actuation sequence beyond the claimed sealing relationships.

The claim does require a particular architecture. The key limitations are:

A sealed reservoir with a dispensing port.
A linear channel communicating with that port.
A separate pressure-relief port in the channel.
A conduit connecting the reservoir interior to that pressure-relief port.
A movable cup assembly with two sealing surfaces.
A recess that alternately aligns with the dispensing port.
Position-dependent sealing of both ports.

The pressure-relief arrangement is likely the principal claim differentiator. A conventional inhaler with a reservoir and sliding metering cup may avoid the claim if it lacks the claimed pressure-relief port and conduit arrangement, even if its dosing function is similar.

What dependent claims add to the patent scope?

How do claims 2, 6 and 7 narrow the inhaler?

Claims 2 and 6 require spring-loaded sealing.

Claim 2 requires a sealing spring that biases the first sealing surface against the reservoir. Claim 6 narrows the architecture further by requiring the cup and cup sled to be separate components, with a sealing spring between them.

Claim 7 requires the channel to extend linearly and the cup assembly to move in opposing directions. This limitation reinforces the translating, rather than rotating, nature of the metering mechanism.

What protection do claims 3, 13 and 16 provide?

Claim 3 requires a collapsible bellows that increases pressure inside the reservoir when collapsed while the pressure-relief port is sealed.

Claim 13 combines that bellows with the three-position yoke arrangement in claim 12. It requires the yoke to collapse the bellows in the first and second positions.

Claim 16 requires a volume of dry powdered medicament in the reservoir. This claim is narrower than claim 1 because it ties the device to the intended dry-powder product configuration.

The bellows limitations may be commercially important because they connect reservoir pressurization to the mechanical sequence. They also provide potential design-around opportunities. A competing product using ambient-pressure powder feeding, vacuum-assisted metering, or a different pressure-generation system may avoid claims 3 and 13 while still requiring analysis under claim 1.

What do claims 4 and 5 cover?

Claim 4 divides the cup assembly into:

A cup received in a cup sled;
A cup-defined recess;
A cup-defined first sealing surface; and
A sled-defined second sealing surface.

Claim 5 adds an indentation in the sled. The indentation aligns with the pressure-relief port and unseals it when the first sealing surface aligns with the dispensing port.

These claims create a component-level limitation. A one-piece metering member may fall outside claims 4 and 5, although it could remain within claim 1 if it still has the required cup assembly and two sealing surfaces.

What do claims 8 through 15 cover?

Claims 8 through 15 protect the actuator and cover sequence.

Claim 8 requires:

A cup spring;
A movable yoke;
A ratchet;
At least two yoke positions; and
Selective blocking or release of cup movement.

Claim 9 requires the spring to bias the cup away from the dispensing port. Claim 10 adds a push bar that moves the recess into alignment with the dispensing port.

Claim 11 introduces a cam with at least two successive cam surfaces. The yoke is spring-biased against the cam, causing sequential yoke movement as the cam moves.

Claim 12 requires three successive cam surfaces and three yoke positions. The ratchet holds the recess away from the dispensing port in two positions and releases the cup assembly in the third.

Claims 14 and 15 tie the cam to a mouthpiece cover. Opening and closing the cover moves the yoke, and claim 15 specifies rotational cam movement.

These claims are materially narrower than claim 1. They are most relevant to products that use a cover-operated, multi-stage loading and metering sequence.

What protection does claim 17 provide for dose counting?

Claim 17 requires a mechanical dose counter with:

A pawl moving along a predetermined path;
A bobbin;
A rotatable spool;
A rolled ribbon;
Indicia on the ribbon;
A first ribbon end secured to the spool;
A second ribbon end positioned on the bobbin; and
Radially extending spool teeth engaged by the pawl.

The claim requires the spool to rotate and advance the ribbon as medicament is metered. This is a specific ribbon-based counter, not a generic dose counter. An electronic counter, printed disk, numbered wheel, or differently actuated mechanical counter may avoid literal infringement of claim 17.

How does the claim set divide infringement risk?

Product configuration	Claim risk
Sealed reservoir, sliding cup, pressure-relief port and conduit	Potential claim 1 risk
Sliding cup without pressure-relief port	Lower literal risk under claim 1
Rotating metering disk	Likely lower literal risk under linear-channel limitations
Bellows-assisted reservoir	Additional risk under claims 3 and 13
Separate cup and sled with springs	Additional risk under claims 4 and 6
Cover-operated three-position cam	Additional risk under claims 11 through 15
Ribbon-and-spool counter	Additional risk under claim 17
Device containing the same mechanics but no dry powder	Claims 1 through 15 may remain relevant; claim 16 is narrower
Drug product sold without the patented inhaler	No direct apparatus infringement merely from the active ingredient

Literal infringement requires every limitation of at least one asserted claim. The doctrine of equivalents could expand practical risk, but its application depends on prosecution history, claim construction, estoppel, and the specific accused design.[2]

What is the patent’s likely technical contribution?

The claim set combines four mechanical functions:

Dose isolation from a sealed bulk reservoir.
Pressure control during reservoir loading and discharge.
Controlled release of a spring-biased metering cup.
Mechanical synchronization of actuation, mouthpiece opening, bellows compression, and dose counting.

The architecture appears designed to reduce uncontrolled powder flow from the reservoir. The pressure-relief port permits a controlled pressure state during cup movement. The sealing surfaces determine whether the reservoir is open to the recess or isolated from it.

The patent is therefore stronger against products that reproduce the complete sequence than against products that merely use a bulk powder reservoir or a metering recess. Its commercial value depends on whether the claimed pressure-relief and actuator arrangement is necessary for the product’s performance or can be replaced without materially affecting dose delivery.

How strong is the patent estate based on the supplied claims?

The individual patent has a layered claim structure:

Protection layer	Claims	Relative breadth
Core reservoir and cup mechanism	1	Broadest
Spring-loaded sealing	2, 6	Narrow
Bellows pressurization	3, 13	Narrow
Cup-and-sled construction	4, 5	Narrow
Linear reciprocating movement	7	Narrow
Ratchet and yoke	8-10	Narrow
Cam sequencing	11, 12	Narrow
Cover-operated actuation	14, 15	Narrow
Dry powder configuration	16	Narrow
Ribbon dose counter	17	Narrow

The claim set has useful fallback positions. If claim 1 were narrowed or found invalid, claims 4, 5, 8, 11, 14 and 17 could preserve protection for specific commercial implementations. That said, the narrower claims depend heavily on product correspondence. A product must reproduce the specified mechanical relationships, not merely the overall result.

Patent strength cannot be assessed from claim text alone. The principal validity issues would likely include:

Anticipation by earlier inhalers using sealed reservoirs and sliding metering cups;
Obviousness based on combining metering-cup, pressure-relief, spring, cam, and counter references;
Written-description and enablement support for the full combination;
Indefiniteness of functional language such as "adapted to";
Claim construction of "cup assembly," "linear channel," and "pressure relief port";
Prosecution-history amendments and disclaimer effects.

Under U.S. law, an apparatus claim can be anticipated only if one prior-art reference discloses every limitation arranged as claimed.[3] Obviousness may be established through a combination of references where the claimed arrangement and motivation to combine satisfy the statutory and case-law standards.[4]

When does U.S. Patent 7,540,282 lose exclusivity?

The patent’s expiration date cannot be established from the claim text or issue number. The relevant calculation uses the earliest effective nonprovisional filing date, adjusted for patent-term adjustment and affected by any terminal disclaimer or patent-term extension. The issue date, June 2, 2009, is not the statutory term start date.[1]

A practical diligence review should distinguish:

Date category	Relevance
Earliest nonprovisional filing date	Usually controls the 20-year patent term
Provisional filing date	Generally does not start the 20-year term
Continuation or divisional filing date	May inherit the parent’s term framework
Patent-term adjustment	Can extend the nominal expiration date
Terminal disclaimer	Can shorten enforceable term
Patent-term extension	Usually relevant to qualifying drug products, not a stand-alone device claim
Maintenance fees	Nonpayment can cause earlier expiration or lapse
Reinstatement	May restore rights subject to statutory requirements

Because the claims are directed to an inhaler rather than a drug substance or drug formulation, the patent is not equivalent to an Orange Book-listed active-ingredient patent. FDA Orange Book listing is generally tied to approved drug products and patent information submitted by the NDA holder under the applicable regulations.[5]

What is the Orange Book status of the patent?

A stand-alone inhaler patent is generally not an Orange Book patent unless it is properly associated with an approved drug product and satisfies FDA listing requirements. The claims supplied here do not identify:

An NDA;
An active ingredient;
A dosage form;
A drug product trade name;
An approved indication; or
A listed formulation.

Accordingly, the patent should be treated as a device or delivery-system patent unless an approved combination product links it to an NDA.

An Orange Book listing would matter because a generic applicant could be required to address listed patents through a Paragraph IV certification or another statutory certification pathway. Without a qualifying drug-product listing, the patent would not ordinarily create the same Hatch-Waxman litigation trigger as a listed drug patent.[5]

What Paragraph IV and generic-entry risks exist?

The patent creates different risks for different market-entry pathways.

Small-molecule dry-powder products

A generic company seeking approval of a dry-powder inhaler may face:

Device equivalence questions;
Pharmaceutical-equivalence requirements;
In-vitro performance comparisons;
Human-factors review;
Device constituent-part requirements;
Patent certifications if the patent is listed for the reference product.

The patent itself does not block a generic active ingredient. It can restrict use of a particular inhaler architecture.

505(b)(2) products

A 505(b)(2) applicant using a patented delivery mechanism may face patent litigation if the mechanism is listed or otherwise asserted. The applicant could pursue a design that uses a different reservoir, metering system, pressure-control mechanism, or counter.

Biosimilars

Biosimilar risk is not directly implicated. The claims do not cover a biologic molecule, biologic formulation, cell line, manufacturing process, or therapeutic method. A biologic delivered through an inhaler could raise device issues, but the patent would not create a biosimilar patent barrier comparable to a composition-of-matter or biologic manufacturing patent.

Which competing inhaler designs are most relevant?

The closest technical comparison is not based on drug identity but on delivery architecture.

Inhaler architecture	Relevance to Patent 7,540,282
Bulk-reservoir inhaler with sliding metering cup	Potentially closest
Blister-based inhaler	May avoid reservoir and pressure-relief limitations
Capsule-based inhaler	May avoid sealed bulk-reservoir architecture
Multi-dose rotating disk	May avoid linear channel and cup-sled limitations
Reservoir inhaler with different pressure control	Possible design-around
Electronic or optical dose counter	May avoid claim 17
Cover-operated inhaler without the claimed cam and yoke	May avoid claims 11 through 15
Metered-dose aerosol inhaler	Usually technically distinct from the dry-powder claims

The most credible design-around strategies would remove or alter one of the following:

The linear channel;
The separate pressure-relief port;
The conduit between the reservoir and relief port;
The dual sealing-surface sequence;
The spring-biased cup;
The three-position cam and yoke;
The ribbon dose counter.

A design that retains the same functional sequence while changing only dimensions or materials may present greater equivalents risk than a design that changes the mechanism itself.

What litigation, licensing, and settlement issues affect the patent?

The supplied claim text does not identify a litigation caption, asserted claim, court, settlement, license, or assignment history. Those matters cannot be inferred from the claims.

For commercial diligence, the relevant questions are:

Whether the patent was asserted against an inhaler manufacturer;
Whether any case construed "pressure relief port" or "cup assembly";
Whether the patent family includes continuations with later-expiring claims;
Whether the rights were assigned or licensed to a device manufacturer;
Whether any settlement permits launch before patent expiration;
Whether a terminal disclaimer links the patent to another patent;
Whether maintenance fees were paid through the relevant term.

A continuation patent could be more commercially significant than the issued patent if it preserves broader or differently drafted claims. A complete freedom-to-operate review therefore requires the entire priority family, related U.S. applications, foreign counterparts, prosecution history, assignment records, maintenance-fee records, and litigation databases.

What geographic coverage does the patent provide?

U.S. Patent 7,540,282 provides rights only in the United States. It does not directly control:

European sales;
Canadian sales;
Japanese sales;
Australian sales; or
Manufacturing performed entirely outside the United States.

Foreign counterparts may create parallel rights, but each jurisdiction applies its own claim construction, validity standards, term rules, maintenance requirements, and enforcement procedures. U.S. manufacturing, importation, or sale can create domestic exposure even where the product is marketed primarily outside the United States.[6]

What is the commercial exposure from this patent?

Commercial exposure depends on the revenue attributable to products using the claimed architecture, not on sales of the active ingredient generally.

The highest exposure would occur where:

One inhaler platform supplies multiple branded products;
The device is used for chronic therapy;
The reservoir and actuator cannot be redesigned without regulatory bridging;
The product has substantial U.S. sales;
The patent is supported by continuations or related patents;
The product’s approved device constituent part is difficult to replace.

Exposure is lower where the manufacturer can substitute a blister, capsule, rotating disk, or alternative metering system without changing the active formulation or requiring extensive clinical work.

Key Takeaways

U.S. Patent 7,540,282 is a mechanical inhaler patent, not a drug-substance patent.
Claim 1 centers on a sealed reservoir, linear channel, pressure-relief port, conduit, and movable cup with two position-dependent sealing surfaces.
Claims 2 through 17 add spring, bellows, cup-sled, ratchet, yoke, cam, mouthpiece-cover, dry-powder, and ribbon-counter limitations.
The pressure-relief architecture is the main structural feature separating the claim set from generic metering-cup concepts.
Products using blister packs, capsules, rotating disks, or materially different pressure-control systems may offer credible design-around paths.
The patent does not inherently create biosimilar risk.
Orange Book relevance depends on whether the patent was properly submitted for an approved drug product.
Exact expiration requires the effective filing date, patent-term adjustment, terminal-disclaimer data, and maintenance-fee status.
The highest commercial risk arises when the patented mechanism is embedded across a large inhaler platform and cannot be replaced without regulatory and manufacturing disruption.

FAQs

Can a generic infringe this patent without copying the same inhaler appearance?

Yes. Infringement depends on the claimed technical elements, not external appearance. A visually different inhaler could infringe if it contains every limitation of an asserted claim.

Does claim 1 require the inhaler to contain dry powder?

No. Claim 1 does not expressly require dry powdered medicament. Claim 16 adds that limitation.

Can a rotating metering disk infringe claim 1?

A rotating disk would face a lower literal-infringement risk because claim 1 requires a linear channel and a cup assembly received in that channel. The result would depend on the actual structure and claim construction.

Does the dose counter in claim 17 cover electronic dose counters?

Not literally. Claim 17 requires a bobbin, rotatable spool, rolled ribbon, indicia, pawl, and spool teeth. An electronic counter would ordinarily lack those structural elements.

Can a company manufacture the inhaler outside the United States and sell it in the United States?

U.S. importation and domestic sale can create infringement exposure even when manufacturing occurs abroad. The analysis depends on the accused acts and the patent’s enforceable term.[6]

Sources:

United States Patent and Trademark Office. (2024). Patent term adjustment and patent term calculation. U.S. Department of Commerce.
United States Code, 35 U.S.C. §§ 271, 273.
United States Code, 35 U.S.C. § 102.
United States Code, 35 U.S.C. § 103; KSR International Co. v. Teleflex Inc., 550 U.S. 398 (2007).
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
United States Code, 35 U.S.C. § 271.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	028746	⤷ Start Trial
Argentina	028747	⤷ Start Trial
Argentina	064449	⤷ Start Trial
Austria	281861	⤷ Start Trial
Austria	415994	⤷ Start Trial
Austria	460955	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,540,282

Summary for Patent: 7,540,282